• Zoubida Tazi Mezalek, Hajar Khibri, Wafaa Ammouri, Majdouline Bouaouad, Soukaina Haidour, Hicham Harmouche, Mouna Maamar, and Mohamed Adnaoui.
• Internal Medicine Department, Ibn Sina University Hospital, Rabat, Morocco.
• Clin. Appl. Thromb. Hemost. 2020 Jan 1; 26: 1076029620948137.

AbstractThe SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of thousands of people infected. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers and fibrinogen. This coagulopathy is associated with an increased risk of death. Furthermore, a substantial proportion of patients with severe COVID-19 develop sometimes unrecognized, venous, and arterial thromboembolic complications. A better understanding of COVID-19 pathophysiology, in particular hemostatic disorders, will help to choose appropriate treatment strategies. A rigorous thrombotic risk assessment and the implementation of a suitable anticoagulation strategy are required. We review here the characteristics of COVID-19 coagulation laboratory findings in affected patients, the incidence of thromboembolic events and their specificities, and potential therapeutic interventions.

40 keywords...

hide…